How to apply for the 340B program?
You can apply for the 340B Drug Pricing Program by submitting an online registration through the HRSA 340B OPAIS portal during quarterly enrollment windows.
đź—“ Registration Windows
- January 1–15: Coverage starts April 1
- April 1–15: Coverage starts July 1
- July 1–15: Coverage starts October 1
- October 1–15: Coverage starts January 1
âś… Eligibility Requirements
- Covered Entity Status: Must be an eligible federal grantee (e.g., FQHC, Ryan White clinic) or a qualifying hospital (e.g., Critical Access, Disproportionate Share).
- CMS Data Mapping: Must exist in CMS data (HCRIS/PECOS) using a valid Medical Provider Number (MPN).
- Non-Profit/Public Status: Must be government-operated or a non-profit organization serving low-income communities.
đź’ˇ Step-by-Step Application Process
- Setup Account: Create a user profile on the HRSA 340B OPAIS system.
- Designate Officials: Assign a legally authorized Authorizing Official (AO) and a Primary Contact (PC).
- Submit Application: Complete the online enrollment forms during an active quarterly window.
- Await Approval: HRSA reviews and verifies facility data against federal records.
How to qualify for the 340B program?
To qualify for the federal 340B Drug Pricing Program, a healthcare organization must be classified as an eligible "covered entity" and complete official registration through the HRSA Office of Pharmacy Affairs Information System (OPAIS).
Eligible Organization Types
Participation is restricted to specific non-profit and public health care providers that serve low-income or underserved populations:
- Federally Qualified Health Centers (FQHCs) and FQHC look-alikes.
- Certain Hospital Types: Disproportionate Share Hospitals (DSH), Children’s hospitals, Free-standing cancer hospitals, Critical Access Hospitals (CAH), Sole Community Hospitals (SCH), and Rural Referral Centers (RRC).
- Federal Grantees: Ryan White HIV/AIDS programs, Title X family planning, Black lung clinics, Sexually Transmitted Disease (STD) clinics, and tuberculosis clinics.
Specific Hospital Requirements
Hospitals must meet precise government-backed operational and financial metrics based on their most recently filed Medicare cost report:
- Medicare DSH Adjustment Percentage: General DSH, children's, and cancer hospitals generally need a DSH percentage above 11.75%. Sole Community Hospitals and Rural Referral Centers require 8% or greater. Critical access hospitals have no specific DSH percentage requirement.
- Group Purchasing Organization (GPO) Prohibition: DSH, children's, and freestanding cancer hospitals must certify they will not use a GPO to buy covered outpatient drugs.
Patient Eligibility Rules
For an individual to receive a 340B-priced drug, they must meet strict criteria proving a direct care relationship with the covered entity:
- Must be an established patient of the covered entity (with maintained medical records documenting care).
- Must receive healthcare services from a provider employed by or under a formal contractual/referral arrangement with the covered entity.
- The service provided must be consistent with the scope of care the facility is authorized to provide under the 340B program.
Registration Windows
Organizations can only submit new enrollments during quarterly two-week windows managed by HRSA:
- January 1–15 (Effective April 1)
- April 1–15 (Effective July 1)
- July 1–15 (Effective October 1)
- October 1–15 (Effective January 1)
What does a 340B cost?
A 340B drug price does not have a single flat cost; instead, it is a ceiling price calculated for each specific medication using a statutory formula: the Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA).
How the Cost is Calculated
- The Formula: 340B Ceiling Price = (AMP - URA) x Package Size x Case Pack Size
- Average Savings: Eligible healthcare organizations ("covered entities") typically save between 20% to 50% (and sometimes up to 60%) off standard wholesale drug prices.
- Extreme Lows: In some cases, high-volume or heavily rebated drugs can cost the purchasing hospital as little as a penny, though the hospital generally bills private insurance or Medicaid at standard rates to generate revenue for patient care.
Who Qualifies for 340B Prices
The discounted pricing is not available to the general public or regular commercial pharmacies. It is restricted to designated covered entities:
- Disproportionate share (DSH) hospitals serving low-income communities
- Children's and free-standing cancer hospitals
- Critical access and sole community rural hospitals
- Federally funded health centers and Ryan White HIV/AIDS clinics
What is the 340B program and how does it apply to hospitals?
A 340B hospital is a healthcare facility that qualifies under federal law to buy outpatient prescription drugs at deep discounts from pharmaceutical manufacturers.
How the 340B Program Works
Congress created the 340B Drug Pricing Program in 1992 under Section 340B of the Public Health Service Act. It is managed by the Health Resources and Services Administration (HRSA).
- Drug companies that want their products covered by Medicaid must sell outpatient drugs to eligible safety-net providers at reduced prices.
- Discounts typically range from 25% to 50% off regular drug prices.
- Hospitals use these savings to fund free care, lower medication costs, or build community health clinics.
Which Hospitals Qualify?
To be a 340B hospital, a facility must be a public or non-profit organization that serves a high number of low-income or uninsured patients. Qualifying types include:
- Disproportionate Share Hospitals (DSH) that serve many low-income patients
- Children's and cancer hospitals
- Sole community hospitals and rural referral centers
- Critical access hospitals in rural areas
You can review specific criteria on the 340B Health Overview.
Why the Program is Controversial
- Supporters (like the American Hospital Association) say the program is vital for keeping rural and urban safety-net hospitals open. Read more on the AHA Fact Sheet.
- Critics (like pharmaceutical associations) argue that the program has grown too large and that some hospitals use the profits for non-patient expenses rather than direct community care.
What hospitals are eligible for 340B?
Hospitals eligible for the 340B drug pricing program must be non-profit, government-owned, or public safety-net institutions that serve a high volume of low-income or uninsured patients.
🏥 Eligible Hospital Types
- Disproportionate Share Hospitals (DSH): Non-profit/public hospitals with a high proportion of low-income patients.
- Critical Access Hospitals (CAH): Small, rural facilities providing essential services.
- Sole Community Hospitals (SCH): Rural hospitals serving as the sole provider in an area.
- Rural Referral Centers (RRC): Larger rural hospitals receiving specialized referral patients.
- Children’s Hospitals: Specialized pediatric facilities.
- Free-Standing Cancer Hospitals: Specialized independent oncology facilities.
⚠️ Ownership and Legal Status
- Non-Profit or Public: Must be a unit of state/local government or a non-profit organization.
- For-Profit Exclusion: Most for-profit hospitals are strictly ineligible.
- DSH Adjustment: Must meet specific federal low-income patient percentage thresholds (typically an 11.75% DSH adjustment percentage or higher depending on the category).
đź’ˇ Program Registration
- HRSA Approval: Must officially register and get approved through the HRSA 340B OPAIS portal.
- Recertification: Must complete annual recertification to maintain active status.
340B Simplified
Which drugs are covered by 340B?
The 340B Drug Pricing Program covers almost all outpatient prescription drugs and drugs administered by physicians in an outpatient setting, as long as the manufacturer participates in Medicaid.
The 340B Drug Pricing Program | HRSA manages this federal initiative, which applies broadly to brand-name and generic drugs rather than a restrictive list of specific medications.
Included and Excluded Categories
- Included: Outpatient brand-name prescription drugs, generic drugs, and clinician-administered outpatient drugs. Top spending categories include oncology, immunology, and chronic disease treatments (such as Keytruda, Biktarvy, and Eliquis).
- Excluded: Vaccines are generally not covered under the 340B discount structure. Inpatient drugs do not qualify because the statutory discount applies strictly to outpatient care.
- Drugmaker Participation: Any drug covered by Medicaid requires the manufacturer to provide these discounted prices to eligible safety-net providers.
What are the risks of the 340B program?
The primary risks and criticisms of the 340B Drug Pricing Program involve a lack of federal oversight, financial exploitation by hospitals, and growing legal and operational instability for participating providers.
Lack of Transparency and Oversight
- No Mandate for Savings: The federal law does not require hospitals or covered entities to pass 340B drug discounts directly to uninsured or low-income patients at the pharmacy counter.
- Limited Enforcement: The Health Resources and Services Administration (HRSA) has limited tools, staff, and legal authority to audit and monitor tens of thousands of participating entities effectively.
- Unclear Revenue Use: Hospitals are not legally required to report how they use the profit margins generated from buying drugs at a 25% to 50% discount and billing them at standard rates.
Financial Exploitation and System Abuse
- Hospital Consolidation: Critics and industry watchdogs point out that the profit potential incentivizes large hospital systems to acquire independent community oncology, rheumatology, and primary care practices.
- Expansion into Affluent Areas: Rather than exclusively serving low-income or rural populations, many participating 340B clinics and contract pharmacies operate in wealthier, well-insured neighborhoods.
- Duplicate Discounts: Audits by the Government Accountability Office (GAO) have flagged instances of illegal "duplicate discounting," where a single prescription improperly receives both a 340B price break and a Medicaid statutory rebate.
Operational and Legal Threats to Providers
- Manufacturer Restrictions: Dozens of drug manufacturers have restricted shipping discounted medications to external contract pharmacies, significantly reducing revenue for safety-net hospitals.
- Compliance and Administrative Burdens: New data-sharing demands and changing federal survey requirements from the Centers for Medicare & Medicaid Services (CMS) force hospitals to invest heavily in compliance staffing and IT upgrades just to maintain eligibility.
Who pays for 340B drugs?
Pharmaceutical manufacturers fund the 340B Drug Pricing Program by providing mandatory discounts on outpatient prescription drugs, meaning taxpayers do not directly finance the acquisition cost.
How the Financial Flow Works
- Manufacturers: Pharmaceutical companies absorb the cost of the initial discount. By law, to participate in Medicaid and Medicare Part B, companies must sell outpatient drugs to eligible safety-net providers at reduced ceiling prices (saving entities roughly 25% to 50%).
- Covered Entities: Eligible healthcare organizations—such as disproportionate share hospitals, community health centers, and clinics—buy the drugs at these deep discounts from manufacturers.
- Payers and Patients: When a patient receives the drug, the covered entity bills the patient's insurance (like Medicare, Medicaid, or commercial insurance) or the uninsured patient at standard or higher rates.
- The Revenue "Spread": The difference between the low discounted purchase price paid by the hospital and the standard reimbursement received from insurers or payers is retained by the Covered Entities. Hospitals use this generated revenue ("the spread") to fund uncompensated care, community clinics, and other health services.
Can anyone use a 340B pharmacy?
No, not just anyone can use a 340B pharmacy to get discounted medication pricing.
To receive 340B-priced drugs, you must be an established patient of a registered 340B-covered entity (such as a qualifying community health center, Federally Qualified Health Center, or eligible hospital) and your prescription must stem directly from care received within that specific provider network.
Key Patient Eligibility Rules
- Active Relationship: You must receive medical care from a healthcare provider at the specific 340B-eligible clinic or hospital.
- Managed Care: The specific prescription must result from an outpatient service or treatment actively managed by that provider.
- Approved Locations: The drugs must be dispensed through the covered entity's in-house pharmacy or an officially approved 340B contract pharmacy linked to your treating provider.
You can verify program guidelines and organizational definitions through the HRSA 340B Eligibility Guide.
Is 340B good or bad?
The 340B Drug Pricing Program is a well-intentioned safety-net initiative with mixed real-world results that spark intense debate between healthcare providers and pharmaceutical companies.
âś… The Good: Supporting Vulnerable Communities
- Lifeline for hospitals: Keeps rural and safety-net providers financially solvent.
- Expands care: Funds uncompensated care, behavioral health, and low-cost clinics.
- Zero taxpayer cost: Discounts are funded entirely by required manufacturer concessions.
⚠️ The Bad: System Loopholes and Criticisms
- Profit windfalls: Large hospital conglomerates capture wide margins via contract pharmacies.
- Rising costs: Pushes higher outpatient spending and inflated system-wide prices.
- Lack of transparency: Weak federal oversight leaves unclear how facilities allocate revenue.
📊 Comparison of Perspectives
| Feature | Provider View (AHA) | Pharma/Critic View (PhRMA) |
|---|---|---|
| Primary Impact | Sustains vital community health services | Enriches large hospital networks |
| Financial Effect | Lowers overall health system burdens | Acts as a hidden tax/cost driver |
| Suggested Action | Protect from manufacturer restrictions | Enforce strict transparency and oversight |